Abstract: The compounds of the formula (II): ##STR1## and pharmaceutically acceptable salts and esters thereof wherein X is a C.sub.1-6 alkylene group; m is 1, 2 or 3; n is 1, 2 or 3; A is oxygen, sulphur, --CH.sub.2 -- or --NR.sup.3 -- wherein R.sup.3 is hydrogen, C.sub.1-6 alkyl, phenyl or phenyl (C.sub.1-6)alkyl; R.sup.1 is hydrogen, oxo, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy or phenyl; and R.sup.2 is hydrogen, oxo, C.sub.1-6 alkyl or phenyl: with the proviso that if m and n are both 1 then A is --CH.sub.2 -- and R.sup.2 is not oxo: have been found to be .beta.-lactamase inhibitors and antibacterial agents. Their preparation and use are described.

Abstract: The compounds of the formula (II): ##STR1## wherein R.sub.3 and R.sub.4 are as defined in relation to formula (I) and R.sub.7 is a nitro, cyano, amino or aminomethyl group, are antibacterial agents and .beta.-lactamase inhibitors. Their use and a process for their preparation are described.

Abstract: Compounds of the formula (II): ##STR1## wherein X is sulphur or oxygen and R is hydrogen or alkyl of 1 to 3 carbon atoms, are useful for their antibacterial, .beta.-lactamase inhibitory activity and synergistic activity when combined with a penicillin or cephalosporin.

Abstract: Compounds of formula (III): ##STR1## and esters, amides and pharmaceutically acceptable salts thereof, wherein A.sup.1 is hydrogen or methyl;A.sup.2 is hydrogen or methyl;n is 1, 2 or 3; andR is hydrogen, chlorine, bromine, hydroxy, nitro, amino or trifluoromethyl,are useful as anti-hyperglycaemic agents and/or anti-obesity agents.

Abstract: An intermediate compound which is a perhydrofuro [3,2-6] pyrrole of the formula: ##STR1## wherein: R.sub.2 is hydrogen or C.sub.1-4 alkyl; andR.sub.3 is C.sub.4-9 alkyl, C.sub.5-7 cycloalkyl or C.sub.5-7 cycloalkyl C.sub.1-6 alkyl;for use in the synthesis of prostacyclin aza analogues having anti-thrombotic activity.

Abstract: Compounds of formula (I): ##STR1## wherein: m is 1 or 2; n is 4 to 8; X is CO, protected CO, or CROH wherein R is hydrogen or C.sub.1-4 alkyl and wherein the OH moiety may be protected; R.sub.1 is hydrogen or CO.sub.2 R.sub.1 represents an ester group in which the R.sub.1 moiety contains from 1 to 12 carbon atoms; R.sub.3 is hydroxy, or protected hydroxy; R.sub.2 and R.sub.4 are separately hydrogen, C.sub.1-9 alkyl, C.sub.5-8 cycloalkyl, C.sub.5-8 cycloalkyl-C.sub.1-6 alkyl, phenyl, phenyl C.sub.1-6 alkyl, naphthyl, naphthyl C.sub.1-6 alkyl, any of which phenyl or naphthyl moieties may be substituted by one or more halogen, trifluoromethyl, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or nitro groups; or R.sub.2 and R.sub.4 taken with the carbon atom to which they are joined represent a C.sub.5-8 cycloalkyl group; and salts thereof; except that when one of R.sub.2 and R.sub.4 is hydrogen or C.sub.1-4 alkyl then the other of R.sub.2 and R.sub.4 cannot be hydrogen or C.sub.

Abstract: The compounds of formula (II): ##STR1## in which R.sub.1 is a hydrogen, fluorine, chlorine or bromine atom or a hydroxyl, hydroxymethyl, methyl, methoxyl, amino, formamido, acetamido, methylsulphonylamido, nitro, benzyloxy, methylsulphonylmethyl, ureido, trifluoromethyl or p-methoxybenzylamino group; R.sub.2 is a hydrogen, fluorine, chlorine or bromine atom or a hydroxyl group; R.sub.3 is a hydrogen, chlorine or bromine atom or a hydroxyl group, R.sub.4 is a hydrogen atom or a methyl group; R.sub.5 is a hydrogen atom or a methyl group; R.sub.6 is a hydrogen, fluorine or chlorine atom or a methyl, methoxyl or hydroxy group; X is an oxygen atom or a bond; Y is an alkylene group of up to 6 carbon atoms or a bond; and Z is an alkylene, alkenylene or alkynylene group of up to 10 carbon atoms, have been found to possess anti-obesity and/or anti-hyperglycaemic activity.

Abstract: Prophylactic or therapeutic method for the treatment of venous thrombosis by administering preferably intravenously to a human in need thereof a pharmaceutically acceptable carrier and an in vivo fibrinolytic enzyme in which the catalytic site essential for fibrinolytic activity is blocked by a group, such as an acyl group, removable by hydrolysis at a rate such that the pseudo-first order rate constant for hydrolysis is in the range of 10.sup.-6 sec.sup.-1 to 10.sup.-3 sec.sup.-1 in isotonic aqueous media at pH 7.4 at 37.degree. C.

Abstract: Substituted benzamides having useful pharmacological properties, pharmaceutical compositions containing the same, pharmaceutically acceptable salts thereof, and procedure for administering said compositions. The active compounds have dopamine antagonist activity which is an effective amount of a compound of formula (I) and the compositions are particularly useful for the treatment of humans suffering from emesis impaired gastro-intestinal motility and disorders of the central nervous system. The administration of the compositions overcomes these disorders of the central nervous system and ordinary additions. The active compounds are characterized by having the formula (I), wherein R.sub.2 and/or R.sub.3 are sulphone groups, preferably either R.sub.2 or R.sub.3 being an aminosulphone or alkylsulphone group, which groups may optionally be substituted by 1 or 2 C.sub.1-6 alkyl groups.

Abstract: Compounds of formula (I): ##STR1## wherein: R.sup.1 is hydrogen, halogen or C.sub.1-4 alkoxy;X is oxygen; NR.sup.3 in which R.sup.3 is hydrogen, C.sub.1-4 alkyl, or -Y-R.sup.2 ; --C.dbd.O; or --CHOH;Y is --CH.sub.2 --CHOH, and when X is --C.dbd.O it may also be --CH.dbd.CH--; andR.sup.2 is C.sub.1-4 alkyl, one carbon atom of which is di- or tri-halogenated;or salts thereof, are useful in promoting growth of ruminants. Processes for their production, veterinary formulations and treatments are described.

Abstract: A skin-care composition, effective in promoting epidermal mitosis, comprising from 20-40% by weight of oil, a non-ionic emulsifying agent in an amount greater than 1% by weight and retinol acetate in an amount from 1,000 to 15,000 IUg.sup.-1. The composition preferably contains butylated hydroxytoluene or butylated hydroxyanisole as an antioxidant.

Abstract: A compound of formula (II) or a pharmaceutically acceptable acid addition salt thereof ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are the same or different and each represents C.sub.1-6 alkyl; R.sup.5 represents hydrogen or C.sub.1-6 alkyl; R.sup.6 represents C.sub.1-6 alkyl, phenyl optionally substituted with up to 3 groups selected from halogen, C.sub.1-6 alkyl, and C.sub.1-6 alkoxy; or benzyl optionally substituted with up to 3 groups selected from halogen, C.sub.1-6 alkyl and C.sub.1-6 alkoxy; or R.sup.5 and R.sup.6 together represent the remaining members of a 5- or 6-membered ring optionally containing an oxygen, sulphur or additional nitrogen atom and being optionally substituted with C.sub.1-6 alkyl, carboxy or C.sub.1-6 alkoxycarbonyl; and R.sup.7 represents C.sub.1-6 alkyl, phenyl optionally substituted with up to 3 groups selected from halogen, C.sub.1-6 alkyl and C.sub.1-6 alkoxy; or benzyl optionally substituted with up to 3 groups selected from halogen, C.sub.1-6 alkyl and C.sub.

Abstract: Vasoconstrictor .alpha.-adrenergic agonists of formula (I)A--B--C (I)wherein, A is a 2-imidazoline group or a guanidine group; B is a chemical bond or a linking group one or two atoms in length; and C is a C.sub.6-10 mono- or bi-cyclic group which is either an aromatic group, a heteroaromatic group containing only one hetero-atom, or a group containing an aromatic moiety; and which group C may be substituted by C.sub.1-4 alkyl, C.sub.1-4 alkoxy, halogen or hydroxyl; or salts thereof, are useful in the treatment and prevention of diarrhoea in livestock. Compositions of these compounds are described.

Abstract: This invention concerns compounds of the formula: ##STR1## and the N-oxides and the pharmaceutically acceptable salts thereof wherein R.sub.1 is phenyl unsubstituted or substituted by fluoro chloro, bromo, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms;R.sub.2 is hydrogen or alkyl of 1 to 4 carbon atoms;R.sub.3 is hydrogen, nitro, amino, ##STR2## in which R.sub.4 is alkyl of 1 to 4 carbon atoms unsubstituted or substituted with up to three chlorine atoms or with three fluorine atoms on the same carbon atoms;R.sub.5 is alkyl of 1 to 4 carbon atomsn has a value of 0, 1 or 2.

Abstract: This invention provides compounds, having major tranquilizing activity, of the formula (II): ##STR1## wherein R.sub.1 is a phenyl group optionally substituted by a fluorine, chlorine or bromine atom or an alkyl or alkoxyl group of up to 3 carbon atoms; R.sub.2 is a hydrogen atom or an alkyl group of up to 4 carbon atoms; R.sub.3 is a hydrogen atom or an amino group, a nitro group or a group of the formula NHCOR.sub.4 or NHCO.sub.2 R.sub.4 where R.sub.4 is an alkyl group of up to 4 carbon atoms optionally substituted by one, two or three chlorine atoms or by three fluorine atoms attached to the same carbon atom; n is 0, 1 or 2; and X is a group of the sub-formula (a), (b), (c) or (d): ##STR2## wherein R.sub.5 is an alkyl group of up to 4 carbon atoms; or a N-oxide thereof of the nitrogen atom to which the CHR.sub.2 --(CH.sub.2).sub.n --R.sub.1 moiety is attached; and salts thereof; pharmaceutical compositions containing them; processes for their preparation; and intermediates useful in said process.

Abstract: Compounds of formula (III): ##STR1## and esters, amides and pharmaceutically acceptable salts thereof, wherein A.sup.1 is hydrogen or methyl;A.sup.2 is hydrogen or methyl; andn is 1, 2 or 3have anti-obesity activity. Methods for their preparation pharmaceutical formulations of the compounds and their use in medicine are described.

Abstract: The tendency of gel toothpastes comprising silica thickeners, such as silica aerogel or precipitated silica, and a fluoride source, such as sodium monofluorophosphate or fluoride, to corrode aluminium tubes can be reduced by incorporating at least 0.01% by weight sodium or potassium hydroxide or carbonate, so that the pH of the toothpaste is at least 8.5.

Abstract: A process for the preparation of 3-dimethylamino-1-phenyl-(m-chlorophenyl)propan-2-ol and its salts which comprises the Raney nickel catalysed reduction of 3-nitro-1-phenyl-(1-m-chlorophenyl)propan-2-ol with simultaneous or subsequent dimethylation and thereafter, if desired, salification.

Abstract: Compounds of the formula (I): ##STR1## wherein R.sub.1 and R.sub.2 are independently selected from a hydrogen atom and a C.sub.1-3 alkyl group;R.sub.3 is a hydrogen atom, a C.sub.1-3 alkyl or C.sub.2-4 acyl group;R.sub.4 is a hydrogen atom or C.sub.1-5 alkyl group;R.sub.5 is a C.sub.1-5 alkyl group, a straight chain C.sub.1-3 alkyl group terminally substituted by a chlorine atom;orR.sub.4 and R.sub.5 are joined so that together with the nitrogen atom to which they are attached they form a 5-, 6- or 7-membered ring optionally containing an oxygen or sulphur atom;R.sub.6 is a hydrogen atom, or a C.sub.1-5 alkyl, phenyl, CF.sub.3 or XH group wherein X is an oxygen or sulphur atom, the dotted line represents a bond, and R.sub.7 is not present; or R.sub.6 is an oxygen atom joined to the ring carbon atom by a double bond, the dotted line is not present, and R.sub.7 is hydrogen;the NR.sub.4 R.sub.5 and OR.sub.

Abstract: Analgesic tablets which comprise an analgesic Medicament and metoclopramide or an acid addition salt thereof, the weight ratio of analgesic to metoclopramide or acid addition salt thereof lying in the range of 50:1 to 250:1, and a process for their preparation.